Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
PROTEUS high-risk cohort: 5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median f/u, but source gives no design, N, or treatment.
Thin day, prostate only. A high-risk benchmark series reports 5-yr BCR-FS 44% / MFS 71% / CSS 92%, biochemical events well ahead of clinical ones, but with no arms, N, or treatment stated the numbers cannot be attributed to surgery, RT, or systemic therapy. Context only, not an RT decision.
read the full digest →Studies · 128
- PROTEUS5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median follow-up in a high-risk cohort.
- MARCAP ConsortiumIPD meta-analysis, 10,853 pts: ADT added to RT improved MFS HR 0.83 and OS HR 0.86; dose escalation improved bRFS only.
- STAR-TREC12-mo TME-free survival 78.5% with LCCRT vs 60.6% with SCRT, HR 1.90 (1.29-2.81), in mrT1-T3bN0 rectal cancer.
- Focal Ablation vs IMRT Toxicity (SEER-Medicare)GI toxicity favored focal therapy at 24mo (11.0% vs 21.5%, OR 0.45) but GU toxicity favored IMRT (41.7% vs 29.3%, OR 1.69).
- NRG-GU0053yr DFS 88.6% SBRT vs 92.1% MH-IMRT, superiority rejected (adjusted HR 1.40, 0.91-2.13); bowel and GU toxicity favored SBRT.
- Testosterone recovery post-ADT discontinuation (podcast review)Review of two datasets: 25% of real-world pts recovered T within 12mo; 54% relugolix vs 3% leuprolide at 90d in HERO.
- Moderately hypofractionated partial breast reirradiation40Gy/15fx PBI re-RT after second lumpectomy: 3yr LR-FS, DR-FS and OS all 86%, no grade 3+ late events (N=11).
- NSABP B-35 margin-width analysis10yr IBTR 5.6% vs 4.0% at 1mm cutoff (abs diff 1.6%), 5.3% vs 3.8% at 2mm (abs diff 1.5%).
- Cardiac Risk After Heart-Sparing Breast RadiotherapyMax LAD ≥12 Gy EQD2: sHR 1.81 (1.04-3.16) for cardiac events; mean heart dose ≥2 Gy null (P=.99), 2223 left-sided pts.
- Organs at Risk Radiation Dose Constraints: 2025 UpdateSFRO 2025 OAR dose-constraint update: normofractionated, moderate hypofractionated and ablative tables across skull base, H&N, lung, breast, oesophagus, liver.
- HERO90-day testosterone recovery to ≥280 ng/dL 53.9% with relugolix vs 3.2% with leuprolide after 48wk ADT.
- BEACON-HCCNew North American HCC allocation framework; expert decisions 96.6% concordant with BEACON vs 72.4% with BCLC 2025 across 29 cases.